MX2021002260A - Compuestos utiles como moduladores de la autofagia mediada por chaperonas. - Google Patents
Compuestos utiles como moduladores de la autofagia mediada por chaperonas.Info
- Publication number
- MX2021002260A MX2021002260A MX2021002260A MX2021002260A MX2021002260A MX 2021002260 A MX2021002260 A MX 2021002260A MX 2021002260 A MX2021002260 A MX 2021002260A MX 2021002260 A MX2021002260 A MX 2021002260A MX 2021002260 A MX2021002260 A MX 2021002260A
- Authority
- MX
- Mexico
- Prior art keywords
- chaperone
- compounds useful
- mediated autophagy
- autophagy modulators
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen compuestos y sales farmacéuticamente aceptables de estos de Fórmula I (ver Fórmula) Ciertos compuestos y sales de Fórmula I son activos como moduladores de CMA. La descripción proporciona composiciones farmacéuticas que contienen un compuesto de Fórmula I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/048821 WO2020046335A1 (en) | 2018-08-30 | 2018-08-30 | Compounds useful as chaperone-mediated autophagy modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002260A true MX2021002260A (es) | 2021-08-11 |
Family
ID=69645323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002260A MX2021002260A (es) | 2018-08-30 | 2018-08-30 | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11834424B2 (es) |
EP (2) | EP4212516A1 (es) |
JP (1) | JP7262141B2 (es) |
KR (1) | KR102628396B1 (es) |
CN (1) | CN112714761A (es) |
BR (1) | BR112021003660A2 (es) |
CA (1) | CA3109899A1 (es) |
IL (1) | IL280902A (es) |
MX (1) | MX2021002260A (es) |
WO (1) | WO2020046335A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404421B (zh) * | 2022-02-28 | 2023-04-28 | 同济大学 | 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1745041T3 (da) | 2004-04-30 | 2012-09-24 | Genentech Inc | Quinoxalin-inhibitorer af hedgehog-signaleringsvejen |
WO2011094708A2 (en) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc | Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
US9512092B2 (en) * | 2013-12-12 | 2016-12-06 | Albert Einstein College Of Medicine, Inc. | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof |
WO2016111957A1 (en) | 2015-01-06 | 2016-07-14 | Albert Einstein College Of Medicine, Inc. | Chloroquinoline triazole compounds, composition and uses |
-
2018
- 2018-08-30 EP EP23157560.6A patent/EP4212516A1/en active Pending
- 2018-08-30 MX MX2021002260A patent/MX2021002260A/es unknown
- 2018-08-30 JP JP2021509972A patent/JP7262141B2/ja active Active
- 2018-08-30 WO PCT/US2018/048821 patent/WO2020046335A1/en active Application Filing
- 2018-08-30 US US17/270,522 patent/US11834424B2/en active Active
- 2018-08-30 CN CN201880096188.0A patent/CN112714761A/zh active Pending
- 2018-08-30 EP EP18931720.9A patent/EP3844155A4/en not_active Withdrawn
- 2018-08-30 KR KR1020217006504A patent/KR102628396B1/ko active IP Right Grant
- 2018-08-30 BR BR112021003660-1A patent/BR112021003660A2/pt unknown
- 2018-08-30 CA CA3109899A patent/CA3109899A1/en active Pending
-
2021
- 2021-02-16 IL IL280902A patent/IL280902A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020046335A1 (en) | 2020-03-05 |
BR112021003660A2 (pt) | 2021-05-18 |
CN112714761A (zh) | 2021-04-27 |
EP3844155A1 (en) | 2021-07-07 |
EP4212516A1 (en) | 2023-07-19 |
KR102628396B1 (ko) | 2024-01-24 |
CA3109899A1 (en) | 2020-03-05 |
IL280902A (en) | 2021-04-29 |
JP7262141B2 (ja) | 2023-04-21 |
US11834424B2 (en) | 2023-12-05 |
AU2018439206A1 (en) | 2021-02-04 |
EP3844155A4 (en) | 2022-08-24 |
US20210317095A1 (en) | 2021-10-14 |
KR20210052455A (ko) | 2021-05-10 |
JP2022511269A (ja) | 2022-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
PH12018501099A1 (en) | Novel biphenyl compound or salt thereof | |
MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2016016528A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
IN2014CN03803A (es) | ||
AR087501A1 (es) | Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 | |
PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
WO2016068580A3 (en) | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
MX2018014813A (es) | Composiciones antibacterianas. | |
MX2021004134A (es) | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. | |
TN2016000491A1 (en) | Carboxamide derivatives. | |
TN2016000489A1 (en) | Carboxamide derivatives. | |
WO2018039077A8 (en) | Therapeutic compounds | |
PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof |